Overview of Myeloma
Optimizing Frontline Therapy for Newly Diagnosed Myeloma
- Standard of care
- When to use alternative approaches
- Future directions
Treating Patients With Relapsed/Refractory Myeloma
- How and when to use new agents
- Treating patients after first progression
- How to manage patients after multiple lines of therapy
- Future directions
Conclusions and Audience Questions
Date / Time
Maimonides Medical Center
Robert Wood Johnson University Johnson Hospital Somerset / Steeplechase Cancer Center
Magnolia Regional Health Center
Melissa Alsina, MD
Head, Multiple Myeloma BMT Program
H. Lee Moffitt Cancer Center & Research Institute
Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York
The goal of this activity is to improve participants' competence in providing optimal care for patients with multiple myeloma.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with myeloma.
- Integrate the newly approved monoclonal antibodies daratumumab and elotuzumab into existing treatment strategies for patients with MM
- Describe laboratory testing interference and potential strategies to assess response to therapy when using monoclonal antibodies to treat patients with MM
- Plan appropriate treatment strategies using the new-generation proteasome inhibitors carfilzomib and ixazomib for individual patients with MM
- Apply data recently presented at major hematology/medical oncology meetings to clinical practice
- Develop a proactive management plan for adverse events associated with new agents used to treat MM
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
1.0 contact hour may be earned for successful completion of this activity.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13664, for 1.0 contact hour.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 4 weeks.
Pharmacist Continuing Education
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program has been assigned ACPE Universal Activity #0797-9999-17-073-L01-P. This program is designated for up to 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit.
Type of Activity: Knowledge
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.